Tyra Biosciences develops clinical-stage precision medicines that target Fibroblast Growth Factor Receptor (FGFR) biology. News about TYRA commonly centers on its SNÅP drug-design platform, oral dabogratinib as an FGFR3-selective inhibitor, and pipeline programs in targeted oncology and genetically defined conditions.
Recurring updates include financial results, scientific conference presentations, clinical-study progress in urologic cancers, achondroplasia, hepatocellular carcinoma and intrahepatic cholangiocarcinoma, and governance or leadership changes. Company announcements also cover investor-conference participation and program descriptions for TYRA-430 and TYRA-200.
Tyra Biosciences (Nasdaq: TYRA) announced its participation in the Cowen 42nd Annual Healthcare Conference from March 7-9, 2022. CEO Todd Harris will be featured in a panel on March 8, 2022, at 9:10 am ET. The event aims to highlight the company's focus on precision oncology and its proprietary SNÅP platform to develop therapies targeting tumor resistance. Investors can access a live webcast on the company's website. Tyra specializes in inhibitors for the Fibroblast Growth Factor Receptor (FGFR) family, crucial in treating various cancers.
Tyra Biosciences (Nasdaq: TYRA) will participate in the 2021 Jefferies London Healthcare Conference on November 18-19, 2021. Management will host a fireside chat and one-on-one investor meetings, with the chat available on-demand from November 18. The company focuses on developing precision oncology therapies to combat tumor resistance, featuring their proprietary SNÅP platform. Their lead product, TYRA-300, targets bladder cancer, while TYRA-200 aims at intrahepatic cholangiocarcinoma.
Tyra Biosciences, Inc. (Nasdaq: TYRA) announced its financial results for the quarter ending September 30, 2021. The company completed a $198.7 million IPO and strengthened its leadership team with key appointments. Cash and cash equivalents reached $312.8 million, expected to fund operations through at least 2024. R&D expenses rose to $5.5 million, while net loss for the quarter was $6.6 million, or $(0.72) per share. TYRA nominated TYRA-200 for clinical development, targeting FGFR2 mutations.
Tyra Biosciences, Inc. (Nasdaq: TYRA) has priced its upsized initial public offering of 10,800,000 shares at $16.00 per share, aiming to raise gross proceeds of $172.8 million. The shares are set to trade on the Nasdaq Global Select Market starting September 15, 2021, with the offering expected to close on September 17, 2021. A 30-day option has been granted to underwriters for an additional 1,620,000 shares. Tyra specializes in precision oncology and is focused on therapies targeting tumor resistance, particularly through its lead product candidate, TYRA-300, for bladder cancer.